Opendata, web and dolomites

StableVax

Commercialisation of a world changing invention for the stabilisation and delivery of vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 StableVax project word cloud

Explore the words cloud of the StableVax project. It provides you a very rough idea of what is the project "StableVax" about.

assist    world    containing    organisation    millions    scientific    2012    tool    human    disable    dry    invitation    auto    buffer    rendered    health    divided    closely    roser    ltd    fails    unnecessary    indispensable    completely    removal    exposed    scientist    stabilisation    lives    introducing    refrigerated    designed    eliminate    storage    optimum    material    standard    100    revolutionary    absorbed    pioneer    liquid    guidance    50    stored    company    frequently    patented    annually    commercialise    stablepharma    keep    stable    fighting    special    global    temperature    innovative    left    porous    effectiveness    variety    error    finely    distinguished    invention    useless    lose    customer    saving    january    tens    sub    incorporated    bruce    inserted    relies    vision    cso    globe    dr    syringe    geneva    compressible    officer    monitored    sensitive    saved    wastage    failings    accreditation    units    series    turn    factory    chief    temperatures    dissolved    constant    biological    chairman    vaccines    cold    chain    vaccination    simply    disease    transported    stabilise    vaccine   

Project "StableVax" data sheet

The following table provides information about the project.

Coordinator
STABLEPHARMA LIMITED 

Organization address
address: 1 QUEEN SQUARE
city: BATH
postcode: BA1 2HA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://stablepharma.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STABLEPHARMA LIMITED UK (BATH) coordinator 50˙000.00

Map

 Project objective

Vaccination is an indispensable tool in fighting disease, annually saving up tens of millions of lives saved across the globe. Vaccines are biological products that are sensitive to temperature change and can lose their effectiveness if exposed to sub optimum temperatures. The delivery of vaccines from the factory to the customer currently relies on a closely monitored cold chain process containing a series of refrigerated storage units, designed to keep the vaccine at a constant temperature. The system frequently fails for a variety of reasons, some technical and some simply due to human error. Currently 50% of the world’s vaccines are rendered useless due to the failings of the present refrigerated ‘cold chain’ delivery systems Stablepharma has a vision to eliminate the global cold chain and unnecessary vaccine wastage by introducing an innovative method to stabilise vaccines allowing them to be transported and stored at a wide-range of temperatures. Our technology involves the ~100% removal of liquid from vaccine dissolved in a special buffer, so that it is left in a completely stable and finely divided dry state absorbed into a, compressible, porous material that is in turn inserted into a standard auto-disable syringe. The process and invention was introduced to the WHO (World Health Organisation, Geneva) by invitation in 2012 and they have been able to assist the company with guidance in the development and accreditation process. Stablepharma Ltd was incorporated in January 2012 to commercialise a revolutionary vaccine stabilisation invention and process developed and patented by our Chief Scientific Officer (CSO) and Chairman, Dr Bruce Roser, a pioneer and distinguished scientist in this field.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STABLEVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STABLEVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More